Biotech Values

[DewDiligence]

Lupin, Yoshindo ink FoB collaboration for Japanese market; lead product candidate is Enbrel:

http://finance.yahoo.com/news/lupin-inks-strategic-joint-venture-144600240.html

Lupin Limited announced today that it has entered into a strategic joint venture agreement with…Japanese pharmaceuticals company, Yoshindo Inc. to create a new entity, YL Biologics (YLB). YLB will be jointly managed by both partners and will be responsible for conducting clinical development of certain Biosimilars including regulatory filings and obtaining marketing authorizations in Japan.

The new entity YLB will in-license Monoclonal Antibodies (mAbs) from Lupin and also partner with other companies across the globe for the Japanese market which already has a clear cut regulatory regime in place for the development and commercialization of Biologicals. Lupin's Etanercept biosimilar…will be the first product to be licensed for clinical development to YLB.